All In Biotech

Drug Trial Radar · NCT06373146

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Last checked: Nov 20, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 392 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

392

Actual

Start

Apr 24, 2024

Primary completion

Dec 15, 2025

Study completion Apr 2, 2026

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Apr 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

Conditions

  • Obesity

Interventions

  • TirzepatideDrug

    Administered SC

  • MibavademabDrug

    Administered SC

  • Tirzepatide-PlaceboDrug

    Administered SC

  • Mibavademab-PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Percent Change from Baseline in Body WeightTime frame: Baseline, Week 48

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Velocity Clinical Research, Gardena

    Gardena, California

  • Irvine Clinical Research

    Irvine, California

  • Velocity Clinical Research, Los Angeles

    Los Angeles, California

  • Velocity Clinical Research, North Hollywood

    North Hollywood, California

  • Velocity Clinical Research, Santa Ana

    Santa Ana, California

  • Velocity Clinical Research, Panorama City

    Van Nuys, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Solaris Clinical Research

    Meridian, Idaho

  • Tandem Clinical Research

    Marrero, Louisiana

  • Velocity Clinical Research - New Orleans

    New Orleans, Louisiana

  • Hassman Research Institute Marlton Site

    Marlton, New Jersey

  • Lillestol Research

    Fargo, North Dakota

  • CTI Clinical Research Center

    Cincinnati, Ohio

  • South Texas Clinical Research

    Corpus Christi, Texas

  • Velocity Clinical Research, Dallas

    Dallas, Texas

  • Juno Research

    Houston, Texas

  • Northwest Clinical Research Center

    Bellevue, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.